Therefore, the combination therapy with DCs plus novel agents including lenalidomide or PD-1 inhibiter may modulate anti-tumor immune deficiency and promote cytotoxicity against MM cells, compared with a DC vaccine alone. Here, PDCD1 is linked to neoplasm.